Keros Therapeutics(KROS) - 2023 Q4 - Annual Results

Exhibit 99.1 • KER-050 (elritercept) for the treatment of ineffective hematopoiesis to address cytopenias: ◦ Engage with regulators on the design of the planned Phase 3 clinical trial of KER-050 in patients with MDS in the first half of 2024 ◦ Report additional data from Part 2 of the ongoing Phase 2 clinical trial of KER-050 in patients with MDS in the second and fourth quarters of 2024 ◦ Report additional data from the ongoing Phase 2 clinical trial of KER-050 in patients with myelofibrosis in the second ...